For a broader overview of this class and the kinds of effects people commonly notice, our GLP-1 side effects overview can help put the sleep conversation into context
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
These effects appear to be mediated at least in part through the modulation of reward pathways in the CNS
Although GLP-1R agonists have yielded promising results in animal models, AD transgenic mice do not fully mimic the complex pathology of human AD, and there are still some challenges in translating them into effective AD therapies
Its one of the most common questions our team hears, and honestly, its one of the most important